title: [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
abstract: Hypertensive cigarette smokers run particularly high risk of coronary heart disease. Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be a suitable agent for treating these patients. The effects on blood pressure and metabolic parameters were investigated in a 16-week, open, parallel, comparative study comprising 64 heavy cigarette smokers and 69 non-smokers who received doxazosin after four weeks on placebo. Eight patients (three smokers and five non-smokers) dropped out due to adverse effects. Blood pressure was significantly reduced in both groups, but there was no change in heart rate. Doxazosin induced a decrease in the triglyceride, total cholesterol and LDL-cholesterol levels, and an increase in HDL-cholesterol concentration. Thus, doxazosin has favourable effects on atherogenic factors in smoking hypertensive patients. There was also a significant lowering of plasma fibrinogen levels and plasminogen activator inhibitor (PAI-1) concentration in non-smokers.
authors.affiliation: Klinisk kjemisk avdeling, Ullevål sykehus, Oslo.
authors.forename: L N
authors.initials: LN
authors.lastname: Daae
authors.forename: P
authors.initials: P
authors.lastname: Kierulf
authors.forename: B
authors.initials: B
authors.lastname: Brusletto
authors.forename: A
authors.initials: A
authors.lastname: Westheim
authors.forename: I
authors.initials: I
authors.lastname: Holme
authors.forename: J O
authors.initials: JO
authors.lastname: Syvertsen
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects*; D017292:Doxazosin; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000097:blood*; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012907:Smoking / Q000009:adverse effects* / Q000097:blood / Q000503:physiopathology
chemical_list: D008055:Lipids; D015849:Plasminogen Inactivators; D005340:Fibrinogen; D017292:Doxazosin; D011224:Prazosin
vernacular_title: Effekten av doxazosin på blodtrykk, lipider, fibrinogen og plasminogenaktivator-inhibitor. En sammenliknende studie hos røykere og ikke-røykere med essensiell hypertensjon.